← Back to Screener
Valneva SE American Depositary Shares (VALN)
Price$5.97
Favorite Metrics
Price vs S&P 500 (26W)-49.36%
Price vs S&P 500 (4W)-48.11%
Market Capitalization$530.64M
All Metrics
Book Value / Share (Quarterly)$0.72
P/TBV (Annual)7.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-21.52%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-30.55%
Gross Margin (TTM)29.15%
Net Profit Margin (TTM)-38.70%
EPS (TTM)$-1.14
10-Day Avg Trading Volume1.09M
EPS Excl Extra (TTM)$-1.14
Revenue Growth (5Y)9.62%
EPS (Annual)$-0.81
ROI (Annual)-36.75%
Gross Margin (Annual)38.66%
Net Profit Margin (5Y Avg)-39.98%
Cash / Share (Quarterly)$0.75
Revenue Growth QoQ (YoY)76.88%
ROA (Last FY)-28.88%
Revenue Growth TTM (YoY)29.55%
EBITD / Share (TTM)$-0.65
ROE (5Y Avg)-60.52%
Operating Margin (TTM)-27.38%
Cash Flow / Share (Annual)$-0.39
P/B Ratio4.24x
P/B Ratio (Quarterly)6.05x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.70x
Net Interest Coverage (TTM)-2.56x
ROA (TTM)-37.47%
EV / EBITDA (TTM)22.22x
EPS Incl Extra (Annual)$-0.81
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)1.85x
3-Month Avg Trading Volume1.17M
52-Week Price Return-13.77%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.57
P/S Ratio (Annual)2.58x
Asset Turnover (Annual)0.44x
52-Week High$5.42
Operating Margin (5Y Avg)-28.31%
EPS Excl Extra (Annual)$-0.81
CapEx CAGR (5Y)-25.46%
Tangible BV CAGR (5Y)14.81%
26-Week Price Return-45.57%
Quick Ratio (Annual)1.85x
13-Week Price Return-39.59%
Total Debt / Equity (Annual)1.95x
Current Ratio (Quarterly)2.38x
Enterprise Value$645.597
Revenue / Share Growth (5Y)-3.10%
Asset Turnover (TTM)0.71x
Book Value / Share Growth (5Y)-6.39%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.06x
Pretax Margin (Annual)-65.34%
Cash / Share (Annual)$0.75
3-Month Return Std Dev93.55%
Gross Margin (5Y Avg)34.55%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)41.51%
ROE (Last FY)-108.50%
Net Interest Coverage (Annual)-3.11x
EPS Basic Excl Extra (Annual)$-0.81
P/FCF (TTM)32.18x
Receivables Turnover (TTM)10.20x
Total Debt / Equity (Quarterly)1.95x
EPS Incl Extra (TTM)$-1.14
Receivables Turnover (Annual)5.54x
ROI (TTM)-47.24%
P/S Ratio (TTM)1.40x
Pretax Margin (5Y Avg)-39.29%
Revenue / Share (Annual)$1.22
Tangible BV / Share (Annual)$0.57
Price vs S&P 500 (52W)-43.83%
Year-to-Date Return-29.59%
5-Day Price Return-0.46%
EPS Normalized (Annual)$-0.81
ROA (5Y Avg)-17.08%
Net Profit Margin (Annual)-65.95%
Month-to-Date Return-7.16%
Cash Flow / Share (TTM)$-0.23
EBITD / Share (Annual)$-0.54
Operating Margin (Annual)-46.98%
LT Debt / Equity (Annual)1.52x
ROI (5Y Avg)-26.83%
LT Debt / Equity (Quarterly)1.52x
EPS Basic Excl Extra (TTM)$-1.14
P/TBV (Quarterly)7.66x
P/B Ratio (Annual)6.05x
Inventory Turnover (TTM)2.97x
Pretax Margin (TTM)-37.91%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-39.65%
Beta2.10x
P/FCF (Annual)3.81x
Revenue / Share (TTM)$2.15
ROE (TTM)-109.23%
52-Week Low$2.34
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VALNValneva SE American Depositary Shares | 1.40x | 29.55% | 29.15% | — | $5.97 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Valneva SE is a vaccine company with marketed products for travelers, including IXIARO, DUKORAL, and IXCHIQ. The company generates revenue primarily from vaccine sales while maintaining development programs for new vaccine candidates and COVID-19 vaccine initiatives. Additional revenue streams include technology licensing and manufacturing services.